This protocol addresses pulmonary sarcoidosis presenting with mild respiratory symptoms — specifically cough without dyspnea — in patients where the preceding corticosteroid regimen did not achieve the expected improvement in lung function.
The patient has pulmonary sarcoidosis with mild symptoms:
Cough
Dyspnea is absent. For patients with mild symptoms such as a cough, an initial course of corticosteroid therapy is the standard starting point. However, when that course does not produce the expected respiratory benefit, a different approach is warranted.
The preceding regimen consisted of a prednisone taper. The goal of that line was to achieve improved forced vital capacity within 1–3 months.
When that target is not met — or when corticosteroid-related toxicity becomes a limiting factor — the protocol escalates to this next line of treatment.
The next step involves introducing a steroid-sparing agent: a class of medications that can sustain disease control while reducing reliance on corticosteroids. This approach takes time to establish a clinical response.
The complete agent selection, criteria, monitoring plan, and sequencing are available in the full protocol below.Clinical effectiveness within 6 months is the benchmark for this line of treatment.